Skip to main content

Journal News

Feinstein Institutes, Molecular Medicine award Dr. Peter Hotez with the 2023 Cerami Award. More information on the Anthony Cerami Award can be found here.

Congratulations to Dr. Michelle Monje, winner of the 2024 Ross Prize in Molecular Medicine for her work on neuron-glial interactions with implications for malignant glioma. More information on the Ross Prize in Molecular Medicine can be found here.

Dr. Betty Diamond elected to National Academy of Sciences

Please join us in congratulating Dr. Betty Diamond, Editor in Chief of Feinstein’s flagship journal Molecular Medicine, on her election to the National Academy of Sciences.
Please find further details regarding the announcement here.

Call for Papers: Novel Technologies in Radiotherapy

Edited by:
Shuyu Zhang, PhD, Sichuan University, China
Jianping Cao, PhD, Soochow University, China
Xiaobo Du, PhD, University of Electronic Science and Technology of China, China

Call for Papers: Evolutionary Aspects of Metabolic Diseases

Edited by:
Dimitar Avtanski, PhD, The Feinstein Institutes for Medical Research, USA

Aims and scope

Molecular Medicine is an open access journal publishing recent findings that elucidate disease pathogenesis at the molecular or physiological level, which may lead to the design of specific tools for disease diagnosis, treatment, or prevention. Manuscripts containing material relevant to the genetic, molecular, or cellular basis of key physiologic or disease processes are considered for publication. Manuscripts submitted to Molecular Medicine should describe the implications of the results for human disease and medicine, at a level approachable by our broad audience.

Criteria to consider for studies involving lnc-RNAs or micro-RNAs:

·        As lncRNAs and miRNAs have multiple targets, claims of their function mediated by a single target or pathway will not be accepted, unless multiple additional targets are investigated to support functional specificity.

·        The rationale to investigate a specific lncRNA or miRNA needs to be specified upfront in the introduction and justified in the context of other miRNAs known to be functional in that specific field.

·        The proposed function of the lnc-RNA or miRNA should be validated by gain and loss of function studies.

·        Primary cells should be used whenever possible to confirm findings in cell lines.

·        In depth investigation in the signaling pathway(s) regulated by the RNA species should be conducted.

·        Insight into the regulation of the RNA species and how it relates to the pathologic state should be provided.

·        If applicable: Details of initial screen used to identify RNA species involvement in pathway/disease (number of subjects, statistical tests employed, percent change from controls).

Nobel congratulations to William G. Kaelin Jr

New Content ItemMolecular Medicine is happy to congratulate William G. Kaelin Jr on being a winner of The Nobel Prize in Physiology or Medicine 2019. Professor Kaelin Jr was chosen for his work on the discoveries of how cells sense and adapt to oxygen availability. He previously contributed an article to our journal, "The Molecular Basis of Von Hippel-Lindau Disease", which you can read here.


MOME Reviewers of the Quarter

Molecular Medicine would like to recognize the efforts of the following peer reviewers, for their excellent service during 2024. These individuals have all exceeded expectations as far as acceptance rate, the number of completed reviews, and timeliness. The journal cannot succeed without its peer reviewers, and we thank these hard-working members of our network:
First Quarter of 2024: Dr. Jialin Fu

Articles

Top 10: Most Cited Articles of 2023 and 2022

The semantics of microglia activation: neuroinflammation, homeostasis, and stress
Samuel C. Woodburn, Justin L. Bollinger and Eric S. Wohleb 

Inflammation after spinal cord injury: a review of the critical timeline of signaling cues and cellular infiltration
Daniel J. Hellenbrand, Charles M. Quinn, Zachariah J. Piper, Carolyn N. Morehouse, Jordyn A. Fixel & Amgad S. Hanna

The association of neutrophil to lymphocyte ratio, platelet to lymphocyte ratio, and lymphocyte to monocyte ratio... 
Gong, P., Liu, Y., Gong, Y. et al. 

Mer regulates microglial/macrophage M1/M2 polarization and alleviates neuroinflammation following traumatic brain injury
Wu, H., Zheng, J., Xu, S. et al. 

Edaravone ameliorates depressive and anxiety-like behaviors via Sirt1/Nrf2/HO-1/Gpx4 pathway
Dang, R., Wang, M., Li, X. et al. 

Isoliquiritin ameliorates depression by suppressing NLRP3-mediated pyroptosis via miRNA-27a/SYK/NF-κB axis
Yuanjie Li, Wen Song, Yue Tong, Xia Zhang, Jianjun Zhao, Xiaojuan Gao, Jingjiao Yong & Hanqing Wang 

Neuromyelitis optica spectrum disorders: from pathophysiology to therapeutic strategies
Edgar Carnero Contentti and Jorge Correale

Uncovering sex differences of rodent microglia
Jinming Han, Yueshan Fan, Kai Zhou, Klas Blomgren & Robert A. Harris

Sirtuin 3 protects against anesthesia/surgery-induced cognitive decline in aged mice by suppressing hippocampal neuroinflammation
Liu, Q., Sun, YM., Huang, H. et al. 

Microglia in depression: an overview of microglia in the pathogenesis and treatment of depression
Haixia Wang, Yi He, Zuoli Sun, Siyu Ren, Mingxia Liu, Gang Wang & Jian Yang

Featured cross-journal series: Molecular mechanisms and therapeutic relevance of neuro-immune communication

New Content ItemOur new cross-journal thematic series (published in conjunction with Bioelectronic Medicine), calls for submissions focusing on the molecular mechanisms and therapeutic exploration at the interface between the immune and nervous systems in health and disease and the therapeutic exploration of this insight. It will also cover emerging areas such as the neuronal regulation of hematopoiesis and innate and adaptive immunity. The series is guest edited by Sangeeta Chavan, Colin Reardon, and Niccolò Terrando. Find more information here

Awards

Anthony Cerami Award in Translational Medicine
Molecular Medicine has established the Anthony Cerami Award in Translational Medicine to honor investigators who have created the fundamental innovation necessary for molecular medicine to advance into clinical practice.  The award recognizes leading edge discoveries that have led to improvement of human health, and have opened the door to new therapeutic advances and understanding. Find out more.

Ross Prize in Molecular Medicine
The annual Ross Prize in Molecular Medicine is established in conjunction with the Feinstein Institutes for Medical Research and Molecular Medicine. The winner will be an active investigator having produced innovative, paradigm-shifting research that is worthy of significant and broad attention in the field of molecular medicine. Find out more. Please see more information about the 2024 Ross Prize Symposium on Cancer Neuroscience here

Announcing our new article types

Our journal is proud to offer four new article types, ready for submissions! 

  • Mini-reviews, which provide a concise summary of a specific research topic or field relevant to our scope
  • Perspectives, which grants the opportunity to write about the current state and recent developments of a research field or topic within our scope and point to associated challenges and future directions
  • Opinions, written with a specific focus on a previously published article which has had a major impact on the field.
  • Commentaries, invited pieces which provide further discussion on a primary research manuscript. 

Please see our Submission Guidelines page for more.

About the Editors

​​​​​New Content ItemDr Betty Diamond (Editor-in-Chief) graduated with a BA from Harvard University and an MD from Harvard Medical School. She performed a residency in Internal Medicine at Columbia Presbyterian Medical Center and received postdoctoral training in immunology at the Albert Einstein College of Medicine.
Dr Diamond has headed the Rheumatology Divisions at Albert Einstein School of Medicine and at Columbia University Medical Center. She also directed the Medical Scientist Training Program at Albert Einstein School of Medicine for many years. She is currently head of the Center for Autoimmune, Musculoskeletal and Hematopoietic Diseases at The Feinstein Institutes for Medical Research and Director of the PhD and MD/PhD programs at the Zucker School of Medicine at Hofstra-Northwell.
A past president of the American Association of Immunology, Dr Diamond has also served on the Board of Directors of the American College of Rheumatology and the Scientific Council of the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS). Dr Diamond is a Fellow of the American Association for the Advancement of Science (AAAS), a member of the National Academy of Medicine, and a member of the National Academy of Sciences.

New Content ItemDr Valentin Pavlov, PhD (Executive Editor) is a Professor at the Feinstein Institutes for Medical Research, Northwell Health, and Professor at the Zucker School of Medicine at Hofstra/Northwell. He received his PhD in Physiology, Pathophysiology and Pharmacology from Sofia University "St. Kliment Ohridski" in Sofia, Bulgaria. Following a post-doc at Robert Gordon University, Aberdeen, UK, he joined the Feinstein Institutes in 2002. 
Dr Pavlov’s current research focuses on the role of the brain and vagus nerve cholinergic signaling in the regulation of inflammation and metabolism, and the use of novel cholinergic therapeutic approaches in sepsis and obesity-driven disorders. 
Dr Pavlov is a member of several scientific societies, including Society for Neuroscience, American Physiological Society, American Association of Immunologists, and American Society for Pharmacology and Experimental Therapeutics. He is an Elected Fellow of the American Institute for Medical and Biological Engineering and President of the International Society for Autonomic Neuroscience.

New Content Item (1)Dr. Rosamaria (Maria) Ruggieri, PhD (Managing Editor) is an Associate Professor at the Karches Center for Oncology Research, Feinstein Institutes for Medical Research and at the Department of Molecular Medicine, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell. Dr. Ruggieri received her PhD in Biology from the Weizmann Institute of Science, Rehovot, Israel. After post-doc at DNAX, Palo Alto, and 6 years at ONYX Pharmaceuticals, Richmond, California, she moved to New York where she has been working at the Feinstein Institutes since 2001. Her work has centered on signaling molecules involved in cancer and during the last ten years it has focused on identifying new therapies for pediatric brain tumors.

Shab picDr. Shabirul Haque, PhD, (Managing Editor) is an Investigator at The Feinstein Institute for Medical Research, Northwell Health, Manhasset, New York. Dr. Haque received his MS (Biotechnology) from Aligarh Muslim University (AMU) and PhD (Biomedical sciences) from All India Institute of Medical Sciences (AIIMS), New Delhi, India. He joined the Feinstein Institute for Medical Research in 2009.
Over the span of 20 years of his research career he acquired vast experience in numerous areas, including in vaccine research (conjugate, recombinant and peptide vaccine) leading to patent and technology transfer. His work in cancer research studying B cell biology, the pathogenesis of acute lymphoid leukemia, the role extracellular vesicles (EVs) and innate immunity in cancer development, lead to multiple peer-reviewed publications. Most recently, he is focusing on understating autoimmune diseases.

New Content ItemDr. Sonya VanPattenPhD (Coordinating Editor) is a research scientist in the Institute of Molecular Medicine at the Feinstein Institutes for Medical Research. Dr. VanPatten received her PhD from the Albert Einstein College of Medicine (Bronx, NY, USA) in the Department of Biochemistry. She later did a post-doc at the Feinstein Institutes in the Department of Medicinal Chemistry.
Dr. VanPatten’s research has been in the fields of lipid metabolism, obesity, immunology and autoimmune disease, neuroscience, and drug discovery and development. Currently, she focuses on scientific writing, synopsis, consultation, project management, and editorial aspects of the Institutes’ journals.

Message from the Editors

The Feinstein Institutes Editorial Team and BMC Rejuvenate Molecular Medicine - 30 July 2018

What happens when the immune system goes rogue?

In her 2017 TEDMED Talk, Editor-in-Chief Dr Betty Diamond discusses the latest insights in autoimmune disease research, and the pivotal role that patients play in studies.

Pre-submission inquiries

The Editors of Molecular Medicine welcome authors to send any pre-submission inquiries they might have, here. We ask that you please include “Pre-submission inquiry” in the subject line of your email and that you include the title and abstract of your proposed submission within the message. Our Editors will do their best to respond to you in a timely manner.

Bioelectronic Medicine

New Content ItemIf you enjoy Molecular Medicine, we invite you to visit Feinstein’s Bioelectronic Medicine (published by BMC). Bioelectronic Medicine focuses on the regulatory functions of the nervous system and technologies that record, stimulate, or block neural signaling to affect specific molecular mechanisms in health and disease. It also features bioelectronic approaches for monitoring and controlling biological processes and for providing insights into disease pathogenesis that can be utilized in new treatments of inflammatory, neurodegenerative, gastrointestinal, and cardiovascular diseases, paralysis, and many other conditions.

About Feinstein Institutes for Medical Research

New Content ItemMolecular Medicine is published in partnership with The Feinstein Institutes for Medical Research. As the research arm of Northwell Health, the largest healthcare provider in New York, it is home to 50 research laboratories and to clinical research throughout dozens of hospitals and outpatient facilities. The Feinstein Institutes include 4,000 researchers and staff who are making breakthroughs in molecular medicine, genetics, oncology, brain research, mental health, autoimmunity, and bioelectronic medicine – a new field of science that has the potential to revolutionize medicine. For more information about how the Feinstein Institutes empower imagination and pioneers discovery, visit FeinsteinInstitute.org.

Annual Journal Metrics

  • Annual Journal Metrics

    Citation Impact 2023
    Journal Impact Factor: 6.0
    5-year Journal Impact Factor: 6.0
    Source Normalized Impact per Paper (SNIP): 0.907
    SCImago Journal Rank (SJR): 1.446

    Speed 2023
    Submission to first editorial decision (median days): 6
    Submission to acceptance (median days): 132

    Usage 2023
    Downloads: 1,105,866
    Altmetric mentions: 1,878